ETPrime

Piramal Pharma Share Price

  • 196.16-0.19 (-0.10%)
  • Volume: 4,790
  • Pre Open
  • Last Updated On: 25 Sep, 2025, 09:01 AM IST
High: "320.00",Open: "269.22",Low: "230.00",
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Piramal Pharma Share Price
  • 196.16-0.19 (-0.10%)
  • Volume: 4,790
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

STRONG BUY

Mean Recos by
9 Analysts

0

0

0

4

5

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Key Metrics

PE Ratio
(x)		266.12
EPS - TTM
(₹)		0.74
MCap
(₹ Cr.)		26,098.46
Sectoral MCap Rank
21
PB Ratio
(x)		3.21
Div Yield
(%)		0.00
Face Value
(₹)		10.00
Beta

Beta

1 Month-
3 Months-
6 Months-
1 Year-
3 Years-

-
VWAP
(₹)		0.00
52W H/L
(₹)
307.90 / 181.73

Piramal Pharma share price insights

View All

  • In the last 2 years, only 2.19 % trading sessions saw intraday declines higher than 5 % .

  • Company has posted a loss of Rs 81.7 cr in Jun 30, 2025 quarter after 3 consecutive quarter of profits. (Source: Consolidated Financials)

  • 50 day moving crossover appeared yesterday. Average price decline of -4.02% within 30 days of this signal in last 5 years.

  • Company witnessed QoQ revenue decline of 28.75%, which is lowest in the last 3 years. (Source: Consolidated Financials)

  • Piramal Pharma Ltd. share price moved down by -1.85% from its previous close of Rs 200.03. Piramal Pharma Ltd. stock last traded price is 196.34

    Share PriceValue
    Today/Current/Last196.34
    Previous Day200.03200.10

InsightsPiramal Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Piramal Pharma Share Price Returns

    1 Day-0.1%
    1 Week-3.53%
    1 Month1.73%
    3 Months-2.87%
    1 Year-13.32%
    3 YearsN.A.
    5 YearsN.A.

    ET Stock ScreenersTop Score Companies

    Check whether Piramal Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Piramal Pharma News & Analysis

    View all Piramal Pharma Share News & Announcements

    Piramal Pharma Share Recommendations

    Recent Recos

    STRONG BUY

    Current

    Mean Recos by 9 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹300
    • OrganizationMotilal Oswal Financial Services
    • BUY
    • Target₹340
    • OrganizationJM Financial
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy5555
    Buy4444
    Hold----
    Sell----
    Strong Sell----
    # Analysts9999
    View all Stock Recommendations

    Piramal Pharma Financials

    • Insights

      • PAT: Slipping to Red

        Company has posted a loss of Rs 81.7 cr in Jun 30, 2025 quarter after 3 consecutive quarter of profits. (Source: Consolidated Financials)

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 28.75%, which is lowest in the last 3 years. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income1,992.112,796.102,216.352,302.861,970.68
      Total Income Growth (%)-28.7526.16-3.7616.86-23.58
      Total Expenses2,003.552,435.842,063.292,092.361,931.20
      Total Expenses Growth (%)-17.7518.06-1.398.35-14.13
      EBIT-11.44360.26153.06210.5039.48
      EBIT Growth (%)-103.18135.37-27.29433.18-88.02
      Profit after Tax (PAT)-81.70153.503.6822.59-88.64
      PAT Growth (%)-153.220.00-83.71--187.53
      EBIT Margin (%)-0.5712.886.919.142.00
      Net Profit Margin (%)-4.105.490.170.98-4.50
      Basic EPS (₹)-0.621.160.030.17-0.67
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income1,150.801,729.311,273.021,390.771,099.96
      Total Income Growth (%)-33.4535.84-8.4726.44-30.32
      Total Expenses984.991,334.391,084.441,085.11963.42
      Total Expenses Growth (%)-26.1823.05-0.0612.63-18.91
      EBIT165.81394.92188.58305.66136.54
      EBIT Growth (%)-58.01109.42-38.30123.86-65.02
      Profit after Tax (PAT)113.14277.27118.80210.0685.27
      PAT Growth (%)-59.20133.39-43.44146.35-68.77
      EBIT Margin (%)14.4122.8414.8121.9812.41
      Net Profit Margin (%)9.8316.039.3315.107.75
      Basic EPS (₹)0.852.090.901.590.64
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022
      Total Revenue9,285.998,346.557,306.666,834.90
      Total Revenue Growth (%)11.2614.236.905.49
      Total Expenses8,944.288,163.967,474.186,393.87
      Total Expenses Growth (%)9.569.2316.9014.27
      Profit after Tax (PAT)91.1317.82-186.46375.96
      PAT Growth (%)411.39--149.60-54.98
      Operating Profit Margin (%)8.347.722.499.74
      Net Profit Margin (%)0.990.21-2.635.73
      Basic EPS (₹)0.690.14-1.573.19
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022
      Total Revenue5,493.064,592.173,784.293,318.54
      Total Revenue Growth (%)19.6221.3514.035.79
      Total Expenses4,581.924,084.553,653.642,881.84
      Total Expenses Growth (%)12.1811.7926.7816.76
      Profit after Tax (PAT)691.40391.2269.50343.05
      PAT Growth (%)76.73462.91-79.74-39.97
      Operating Profit Margin (%)19.4014.007.1515.84
      Net Profit Margin (%)13.088.912.0111.08
      Basic EPS (₹)5.223.050.582.91

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022
      Total Assets15,677.5915,311.8114,522.5612,797.04
      Total Assets Growth (%)2.395.4313.4817.41
      Total Liabilities7,552.127,400.447,749.066,100.44
      Total Liabilities Growth (%)2.05-4.5027.0215.22
      Total Equity8,125.477,911.376,773.506,696.60
      Total Equity Growth (%)2.7116.801.1519.48
      Current Ratio (x)1.541.251.261.34
      Total Debt to Equity (x)0.580.580.810.60
      Contingent Liabilities925.66288.52305.78365.47
      Annual FY 2025 FY 2024 FY 2023 FY 2022
      Total Assets10,391.839,550.888,042.407,208.32
      Total Assets Growth (%)8.8018.7611.5725.22
      Total Liabilities2,939.292,838.812,780.612,140.98
      Total Liabilities Growth (%)3.542.0929.8829.28
      Total Equity7,452.546,712.075,261.795,067.34
      Total Equity Growth (%)11.0327.563.8423.57
      Current Ratio (x)1.531.481.201.29
      Total Debt to Equity (x)0.160.170.310.22
      Contingent Liabilities200.65190.29150.70101.97

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 477.46 cr for investing activities which is an YoY increase of 10.01%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022
      Net Cash flow from Operating Activities892.301,004.54483.89766.42
      Net Cash used in Investing Activities-477.46-434.01-1,338.78-1,812.10
      Net Cash flow from Financing Activities-440.83-422.36817.79794.19
      Net Cash Flow-36.87165.96-31.95-176.79
      Closing Cash & Cash Equivalent182.32219.1953.2385.18
      Closing Cash & Cash Equivalent Growth (%)-16.82311.78-37.51-67.48
      Total Debt/ CFO (x)5.294.5411.385.25
      Annual FY 2025 FY 2024 FY 2023 FY 2022
      Net Cash flow from Operating Activities548.77358.2971.52255.20
      Net Cash used in Investing Activities-549.98-635.52-435.05-1,223.02
      Net Cash flow from Financing Activities-61.74451.38290.12905.74
      Net Cash Flow-64.93174.52-73.41-62.08
      Closing Cash & Cash Equivalent163.87228.8054.2884.65
      Closing Cash & Cash Equivalent Growth (%)-28.38321.52-35.88-42.31
      Total Debt/ CFO (x)2.233.2122.754.32

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022
      Return on Equity (%)1.120.22-2.755.61
      Return on Capital Employed (%)6.405.761.656.54
      Return on Assets (%)0.580.11-1.282.93
      Interest Coverage Ratio (x)3.753.062.486.18
      Asset Turnover Ratio (x)0.590.550.330.34
      Price to Earnings (x)333.331,000.00-43.86-
      Price to Book (x)3.662.161.21-
      EV/EBITDA (x)21.4915.4015.66-
      EBITDA Margin (%)17.2616.7812.0518.68
      Annual FY 2025 FY 2024 FY 2023 FY 2022
      Return on Equity (%)9.275.821.326.76
      Return on Capital Employed (%)12.688.394.048.61
      Return on Assets (%)6.654.090.864.75
      Interest Coverage Ratio (x)10.897.663.7911.59
      Asset Turnover Ratio (x)0.530.500.450.48
      Price to Earnings (x)43.1043.67117.65-
      Price to Book (x)3.992.541.55-
      EV/EBITDA (x)24.6621.9122.18-
      EBITDA Margin (%)23.6018.6712.7320.06

    Financial InsightsPiramal Pharma

    • Income (P&L)
    • Cash Flow

      • PAT: Slipping to Red

        Company has posted a loss of Rs 81.7 cr in Jun 30, 2025 quarter after 3 consecutive quarter of profits. (Source: Consolidated Financials)

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 28.75%, which is lowest in the last 3 years. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 477.46 cr for investing activities which is an YoY increase of 10.01%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Piramal Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Piramal Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Piramal Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Piramal Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Piramal Pharma Technicals

    • Bullish / Bearish signals for Piramal Pharma basis selected technical indicators and moving average crossovers.

      MACD Crossover

      Bearish signal on daily chart

      Appeared on: 24 Sep 2025

      Region: Positive

      Last 4 Sell Signals:29 Aug 2025
      Date10 days Gain/Loss %
      29 Aug 2025-0.78%
      24 Jul 2025-6.49%
      13 Jun 2025-5.10%
      15 May 2025-3.89%

      Average price decline of -4.82% within 10 days of Bearish signal in last 10 years

      20 Day EMA Crossover

      Bearish signal on daily chart

      Appeared on: 24 Sep 2025

      20D EMA: 199.50

      Last 4 Sell Signals:22 Jul 2025
      Date7 days Gain/Loss %
      22 Jul 2025-5.87%
      8 Jul 2025-1.57%
      10 Jun 2025-5.76%
      6 Jun 20250.74%

      Average price decline of -2.27% within 7 days of Bearish signal in last 5 years

      Show More
    • 41%
      Positive Movement since
      1st Jan 2005 on basis
      58%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic199.58202.82207.95197.69194.45192.56187.43

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR5.005.065.37

    Piramal Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Piramal Pharma266.123.211.126.400.5810.648.340.190.691.540.585.29
          Ipca Labs43.934.0810.6115.156.2715.1115.898.8035.142.630.190.99
          Gland Pharma42.313.567.6311.436.227.9419.6612.4342.404.330.030.29
          Ajanta Pharma34.008.3424.2830.1018.3511.0026.0219.8073.562.850.000.00
          J B Chemicals38.627.7119.2124.6915.4316.9222.9416.8342.453.040.000.02
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Syngene Int.
          • Emcure Pharmaceuticals Ltd.
          • Wockhardt
          • Eris Lifesciences
          • OneSource Specialty

          Choose from Stocks

            See All Parameters

          Peers InsightsPiramal Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Piramal Pharma Shareholding Pattern

            • Loading...
              Showing Piramal Pharma Shareholding as on Jun 2025
              CategoryJun 2025Mar 2025Dec 2024Sep 2024
              Promoters34.8634.9534.9534.95
              Pledge0.000.000.000.00
              FII30.8631.4931.6831.73
              DII14.2514.7814.0913.80
              Mutual Funds12.3212.7311.6611.21
              Others20.0318.7819.2819.51
            • Showing Shareholding as on Jun 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters46,33,24,67234.86 %-0.09
              Pledge00.00 %0.00
              FII41,02,65,90630.86 %-0.63
              DII18,94,45,77714.25 %-0.53
              MF16,37,95,42312.32 %-0.41
              Others26,62,11,77520.03 %1.25

            Piramal Pharma MF Ownership

            MF Ownership as on 31 August 2025

            View all Mutual Fund Schemes
            Top Searches:
            Piramal Pharma News Piramal Pharma Quarterly Results Piramal Pharma Dividend Piramal Pharma Q1 ResultsPiramal Pharma Q2 ResultsPiramal Pharma Q3 ResultsPiramal Pharma Q4 Results

            Piramal Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              Jul 30, 2025Jun 13, 2025AGM-
              Jul 28, 2025Jul 18, 2025Board MeetingQuarterly Results
              May 14, 2025Apr 29, 2025Board MeetingAudited Results & Final Dividend
              Mar 23, 2025Feb 19, 2025POM-
              Jan 28, 2025Jan 13, 2025Board MeetingQuarterly Results
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Final1%0.14Jul 16, 2025May 14, 2025
              Final1%0.11Jul 12, 2024May 10, 2024
            • All TypesEx-DateRecord DateAnnounced onDetails
              RightsAug 02, 2023Aug 02, 2023Feb 08, 2023Rights ratio: 5 share for every 46 held at a price of Rs 81.0

            About Piramal Pharma

            Piramal Pharma Ltd., incorporated in the year 2020, is a Small Cap company (having a market cap of Rs 26,098.46 Crore) operating in Pharmaceuticals sector. Piramal Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap and Other Operating Revenue for the year ending 31-Mar-2025. Show More

            • Executives

            • Auditors

            • NP

              Nandini Piramal

              Chairperson
              VV

              Vivek Valsaraj

              Executive Director & CFO
              PD

              Peter DeYoung

              Executive Director
              NL

              Nathalie Leitch

              Non Executive Director
              Show More
            • Deloitte Haskins & Sells LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty Smallcap 100, Nifty 500, BSE 500, + 16 more

            Address

            Ground Floor, Piramal Ananta,Agastya Corporate Park,Kamani Junction,Mumbai, Maharashtra - 400070

            Contact

            [email protected]

            http://www.piramalpharma.com

            More Details

            FAQs about Piramal Pharma share

            • 1. What's Piramal Pharma share price today and what are Piramal Pharma share returns ?
              Piramal Pharma share price is Rs 196.34 as on 24 Sep, 2025, 03:59 PM IST. Piramal Pharma share price is down by 1.85% based on previous share price of Rs 200.03. Piramal Pharma share price trend:
              • Last 12 Months: Piramal Pharma share price moved down 13.24%
              • Last 3 Years: Piramal Pharma Share price moved remain unchanged by N.A.
            • 2. What is the PE & PB ratio of Piramal Pharma?
              The PE ratio of Piramal Pharma stands at 266.12, while the PB ratio is 3.2.
            • 3. What are the returns for Piramal Pharma share?
              Return Performance of Piramal Pharma Shares:
              • 1 Week: Piramal Pharma share price moved down by 3.44%
              • 6 Month: Piramal Pharma share price moved down by 13.40%
            • 4. What is the market cap of Piramal Pharma?
              Piramal Pharma share has a market capitalization of Rs 26,098.46 Cr. Within Pharmaceuticals sector, it's market cap rank is 21.
            • 5. What has been highest price of Piramal Pharma share in last 52 weeks?
              In last 52 weeks Piramal Pharma share had a high price of Rs 307.90 and low price of Rs 181.73

            Trending in Markets

            Top Gainers As on 03:59 PM | 24 Sep 2025

            Tata Investment8,863.50
            725.50 (8.92%)
            Minda Corp.579.10
            44.61 (8.35%)
            Syrma SGS Technology858.40
            40.50 (4.96%)
            SCI232.48
            9.14 (4.10%)
            Deepak Fertilisers1,580.30
            61.71 (4.07%)

            Top Losers As on 03:59 PM | 24 Sep 2025

            Adani Power144.50
            -17.85 (-11.00%)
            Adani Gas667.30
            -55.66 (-7.70%)
            Balrampur Chini469.70
            -26.56 (-5.36%)
            Zen Tech1,533.20
            -70.30 (-4.39%)
            Godrej Properties2,019.10
            -84.60 (-4.03%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Piramal Pharma Share Price
            The Economic Times
            BrowseCompanies: